337 related articles for article (PubMed ID: 24692302)
1. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI.
De Cobelli F; Esposito A; Perseghin G; Sallemi C; Belloni E; Ravelli S; Lanzani C; Del Maschio A
AJR Am J Roentgenol; 2012 Apr; 198(4):809-16. PubMed ID: 22451545
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
[TBL] [Abstract][Full Text] [Related]
6. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
[TBL] [Abstract][Full Text] [Related]
7. Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol.
Cao Y; Huang DQ; Shih G; Prince MR
AJR Am J Roentgenol; 2016 Feb; 206(2):414-9. PubMed ID: 26700156
[TBL] [Abstract][Full Text] [Related]
8. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Unenhanced T1-Weighted Signal Intensities Within the Dentate Nucleus and the Globus Pallidus After Serial Applications of Gadopentetate Dimeglumine Versus Gadobutrol in a Pediatric Population.
Renz DM; Kümpel S; Böttcher J; Pfeil A; Streitparth F; Waginger M; Reichenbach JR; Teichgräber UK; Mentzel HJ
Invest Radiol; 2018 Feb; 53(2):119-127. PubMed ID: 28976476
[TBL] [Abstract][Full Text] [Related]
12. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
13. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs.
Hadizadeh DR; Jost G; Pietsch H; Weibrecht M; Perkuhn M; Boschewitz JM; Keil VC; Träber F; Kukuk GM; Schild HH; Willinek WA
Invest Radiol; 2014 Jul; 49(7):457-64. PubMed ID: 24598442
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
Cheong BY; Duran C; Preventza OA; Muthupillai R
AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
[TBL] [Abstract][Full Text] [Related]
18. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.
Hadizadeh DR; Von Falkenhausen M; Kukuk GM; Schöneseiffen K; Gieseke J; Schild HH; Willinek WA
AJR Am J Roentgenol; 2010 Mar; 194(3):821-9. PubMed ID: 20173166
[TBL] [Abstract][Full Text] [Related]
19. A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.
Tanaka A; Masumoto T; Yamada H; Kurauchi M; Breuer J
Magn Reson Med Sci; 2016; 15(2):227-36. PubMed ID: 26687097
[TBL] [Abstract][Full Text] [Related]
20. Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine.
Fink C; Bock M; Kiessling F; Lichy MP; Krissak R; Zuna I; Schmähl A; Delorme S; Kauczor HU
J Magn Reson Imaging; 2004 Feb; 19(2):202-8. PubMed ID: 14745754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
